FDA approves pembrolizumab for high-risk early-stage triple …
On July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
Jul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA approves pembrolizumab with chemotherapy for …
On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or ...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
Jul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab …
Dec 15, 2023 · Enfortumab vedotin in combination with pembrolizumab is being investigated in an extensive program in multiple stages of urothelial cancer, including two Phase 3 clinical trials in MIBC in EV-304 (NCT04700124, also known as KEYNOTE-B15) and EV-303 (NCT03924895, also known as KEYNOTE-905). The use of enfortumab vedotin in combination with ...
FDA approves pembrolizumab with chemotherapy for HER2 …
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of...
Neoadjuvant Pembrolizumab Improves Event-Free Survival in …
Aug 10, 2021 · The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer. 1 This is the first large, randomized, phase III trial to report a statistically significant ...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
Aug 9, 2022 · Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a clinical trial show.
Pembrolizumab in the Treatment of Breast Cancer
Jul 20, 2022 · In this issue of the Journal, Cortes et al. 1 report that pembrolizumab — a breakthrough therapeutic treatment for patients with advanced triple-negative breast cancer — combined with...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
May 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.